Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candesartan + amlodipine + atorvastatin
- Development stage
- Phase 1
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose oral combination of three antihypertensive and lipid-lowering small molecules: **candesartan cilexetil** (an angiotensin II type 1 receptor antagonist/ARB), **amlodipine** (a dihydropyridine calcium channel blocker), and **atorvastatin** (an HMG-CoA reductase inhibitor/statin). This combination is designed to treat patients with cardiovascular disease or high risk due to coexisting hypertension and hypercholesterolemia, offering comprehensive blood pressure and lipid control in a single tablet.
- Brand names
- no widely accepted international brand name known for the triple fixed-dose combination
- Other names
- candesartan cilexetil + amlodipine + atorvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on candesartan + amlodipine + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candesartan + amlodipine + atorvastatin.